Ascendis Pharma A/SASND
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Denmark · ascendispharma.com
Ascendis Pharma is a Copenhagen-based biopharmaceutical company applying its TransCon prodrug technology platform to build a portfolio of endocrinology, rare disease and oncology therapeutics. Its ADSs trade on Nasdaq under ASND.
Key ratios
FCF / Sales
32.0%TTM
2025
6.3%2024
-84.6%2023
-176.1%
Net margin
70.8%TTM
2025
-31.7%2024
-104.0%2023
-180.5%
ROA
9.6%TTM
2025
-6.9%2024
-17.4%2023
-29.7%
ROE
118.8%TTM
2023
-818.4%
Revenue growth
113.4%TTM
2025
98.0%2024
36.3%2023
421.2%
Recent news
Ascendis to Regain Rights to TransCon Technology in Metabolic and Cardiovascular Diseases
Ascendis Announces Planned $400 Million Share Repurchase Program
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
Ascendis and BioMarin Enter Binding Term Sheet for Global Settlement and License Agreement Related to YUVIWEL (Navepegritide)
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
Track ASND in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer